O,O'- dimethyl- O- (6- chlorobicyclo(3.2.0)heptadiene- 1,5- yl)phosphate

Chostaquick

Also Known As:

DCHP

Networked: 13 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Bridged-Ring Compounds: 1
      - Bridged Bicyclo Compounds
        O,O'-dimethyl-O-(6-chlorobicyclo(3.2.0)heptadiene-1,5-yl)phosphate: 13
- Organophosphorus Compounds: 300
  - O,O'-dimethyl-O-(6-chlorobicyclo(3.2.0)heptadiene-1,5-yl)phosphate: 13
Polycyclic Compounds: 6
- Bridged-Ring Compounds: 1
  - Bridged Bicyclo Compounds
    - O,O'-dimethyl-O-(6-chlorobicyclo(3.2.0)heptadiene-1,5-yl)phosphate: 13

Experts

1.	Hernandez, Rebecca: 2 articles (01/2022 - 12/2021)
2.	Liu, Jingwei: 2 articles (01/2022 - 12/2021)
3.	Meng, Zhaojie: 2 articles (01/2022 - 12/2021)
4.	Zhou, Changcheng: 2 articles (01/2022 - 12/2021)
5.	Barlas, Nurhayat: 2 articles (06/2020 - 09/2017)
6.	Yates, Mark: 2 articles (09/2019 - 01/2018)
7.	Chen, Hong: 1 article (01/2022)
8.	Li, Xiuchun: 1 article (01/2022)
9.	Chen, Jianzhong: 1 article (12/2021)
10.	Gonzales, Miko B: 1 article (12/2021)

Related Diseases

1.	Fetal Weight 08/01/2009 - "DCHP produced fetal growth retardation at 750 mg kg(-1) per day, as evidenced by significant reduction of fetal weight. " 09/01/2017 - "In contrast, there was no change in weight gain of dams in DHP and DCHP exposed groups compared to control, but resorption rate, reduced fetal weight, delayed ossification, placental disruption, and hematologic parameters clearly indicated that in utero DHP and DCHP exposure resulted in intrauterine growth retardation in rats."
2.	Fetal Growth Retardation (Intrauterine Growth Retardation) 08/01/2009 - "DCHP produced fetal growth retardation at 750 mg kg(-1) per day, as evidenced by significant reduction of fetal weight. " 09/01/2017 - "In contrast, there was no change in weight gain of dams in DHP and DCHP exposed groups compared to control, but resorption rate, reduced fetal weight, delayed ossification, placental disruption, and hematologic parameters clearly indicated that in utero DHP and DCHP exposure resulted in intrauterine growth retardation in rats."
3.	Dementia (Dementias) 01/01/2018 - "Evaluating the Impact of the Dementia Care in Hospitals Program (DCHP) on Hospital-Acquired Complications: Study Protocol." 09/18/2019 - "To evaluate the impact of the Dementia Care in Hospitals Program (DCHP) on clinical and non-clinical staff job satisfaction, level of confidence and comfort in caring for patients with cognitive impairment (CI). "
4.	Atherosclerosis 01/01/2022 - "By contrast, DCHP did not affect atherosclerosis development in PXRΔMyeLDLR-/- mice. " 01/01/2022 - "In the current study, LDL receptor-deficient mice with myeloid-specific PXR deficiency (PXRΔMyeLDLR-/-) and their control littermates (PXRF/FLDLR-/-) were used to determine the impact of DCHP exposure on macrophage function and atherosclerosis. "
5.	Hypercholesterolemia 12/01/2021 - "Our studies demonstrate that DCHP activated PXR to induce hypercholesterolemia and ceramide production in mice. "

Related Drugs and Biologics

1.	LDL Receptors (LDL Receptor)
2.	Estrogens (Estrogen)
3.	Ceramides
4.	phenyl-2-aminoethyl sulfide (PAES)
5.	N,N-dinitrosohomopiperazine
6.	Polyethylene (Polythene)
7.	Insulin (Novolin)
8.	Diethylhexyl Phthalate (DEHP)
9.	4-boronic acid benzophenone
10.	dicyclohexyl phthalate